Jing Ning, PhD

Peer-Reviewed Articles

1. Yang B, Qin J, Ning J, Liu Y. Rejoinder to reader reaction "Comment on 'Double robust conditional independence test for novel biomarkers given established risk factors with survival data' by Lucas Kook". Biometrics, 2026. e-Pub 2026. PMID: 41755754.
2. Kanwal F, Lopez C, Ning J, Luster M, Reddy KR, Parikh ND, Singal AG, Marrero JA, Chhatwal J, Feng Z, Page-Lester S, Koay EJ, El-Serag HB. Validation of Texas Hepatocellular Carcinoma Consortium Risk Index in the Hepatocellular Carcinoma Early Detection Strategy Study. Clin Gastroenterol Hepatol, 2026. e-Pub 2026. PMID: 41672261.
3. Esmaeli B, Li Z, Lu TJ, Goldberg H, Ning J, Debnam JM, Frank SJ, Ferrarotto R. Disease-specific and overall survival for patients with lacrimal gland adenoid cystic carcinoma in recent decades. Br J Ophthalmol 110(2):226-232, 2026. e-Pub 2026. PMID: 40866108.
4. Dimitriou, F, Wu, X, Nagarajan, P, Glitza, IC, Zhao, L, Ning, J, Patel, SP, Wargo, J, Futreal, A, Woodman, SE, McQuade, JL, Esmaeli, B. Conjunctival melanoma genomic analysis reveals intermediate tumor mutation burden and genomic overlap with cutaneous melanoma. npj Precision Oncology 9(1), 2025. e-Pub 2025. PMID: 41261164.
5. Senapati, J, Konopleva, M, Issa, GC, Jabbour, EJ, Kadia, TM, DiNardo, C, Borthakur, G, Pemmaraju, N, Short, NJ, Yilmaz, M, Deshmukh, I, Alvarez, J, Loghavi, S, Tang, G, Abbas, HA, Andreeff, M, Bhalla, K, Midde, NM, Said, N, Noyalis, A, Mires, DE, Ning, J, Xiao, L, Ravandi-Kashani, F, Garcia-Manero, G, Kantarjian, HM, Daver, N. A phase 1/2 study of DS-1594 menin inhibitor in relapsed/refractory acute leukemias. Journal of Hematology and Oncology 18(1), 2025. e-Pub 2025. PMID: 41310838.
6. Nguyen, NH, Shin, SJ, Dodd-Eaton, EB, Ning, J, Wang, W. PERSONALIZED RISK PREDICTION FOR CANCER SURVIVORS. Annals of Applied Statistics 19(4):3091-3112, 2025. e-Pub 2025.
7. Ding M, Ning J, He X, Wills A, and Li R. Longitudinal Modeling of Rank-based Global Outcome. Statistics Sinica, 2025. e-Pub 2025.
8. Yang B, Qin J, Ning J, Liu Y. Double robust conditional independence test for novel biomarkers given established risk factors with survival data. Biometrics 81(4), 2025. e-Pub 2025. PMID: 41118241.
9. Lu TJ, Li Z, Manisundaram K, Kim S, Ning J, Esmaeli B. Diagnostic Yield of Routine Metastatic Work-Up in Patients with Conjunctival Melanoma. Semin Ophthalmol 40(6):538-545, 2025. e-Pub 2025. PMID: 39982122.
10. Wang Y, Li W, Li R, Ning J. Dynamic Long-Term Prediction With Intermediate Event Information: A Flexible Model With Bivariate Time-Varying Coefficients. Stat Med 44(18-19):e70240, 2025. e-Pub 2025. PMID: 40847763.
11. Lu T, Anthony C, Jiang X, Ning J, Goepfert R, Esmaeli B. Timing of nodal metastasis in patients with eyelid sebaceous carcinoma and implications for surveillance and survival. Br J Ophthalmol 109(8):903-908, 2025. e-Pub 2025. PMID: 40010760.
12. Huang X, Jiang X, Li R, Ning J. Accounting for Competing Risks in the Assessment of Prognostic Biomarkers' Discriminative Accuracy. Stat Biosci, 2025. e-Pub 2025. PMID: 40852443.
13. Daver N, Senapati J, Kantarjian HM, Wang B, Reville PK, Loghavi S, Yilmaz M, DiNardo CD, Kadia TM, Yassouf MY, Maiti A, Arora S, Montalban Bravo G, Tang G, Borthakur G, Sasaki K, Pemmaraju N, Alvarez J, Nogueras Gonzalez GM, Ning J, Issa GC, Konopleva M, Andreeff M, Ravandi F, Garcia-Manero G, Abbas HA. Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis. Clin Cancer Res 31(12):2386-2398, 2025. e-Pub 2025. PMID: 40198272.
14. Ronaghy, A, Crimini, E, Holla, V, Mills Shaw, KR, Doefler, AM, Campbell, E, Yang, RK, Iorgulescu, JB, Patel, KP, McPherson, DD, Ning, J, Meric-Bernstam, F, Karp, DD. Clinical outcomes of tumor-agnostic targeting of BRAF, tumor mutation burden-high, and RET. ESMO Open 10(6), 2025. e-Pub 2025. PMID: 40460677.
15. Do J, Wang Y, Aung PP, Nagarajan P, Ning J, Curry JL, Ivan D, Lenskaya V, Torres-Cabala CA, Prieto VG, Cho WC. INSM1: A highly sensitive marker for primary and metastatic Merkel cell carcinoma, superior to SOX11, pancytokeratin, and CK20. Hum Pathol 160:105838, 2025. e-Pub 2025. PMID: 40505699.
16. Ronaghy A, Crimini E, Holla V, Mills Shaw KR, Doerfler AM, Campbell E, Yang R, Iorgulescu B, Patel KP, McPherson D, Ning J, Karp DD. Clinical Outcomes of Tumor-Agnostic Targeting of BRAF, Tumor Mutation Burden-high, and RET. ESMO Open 10(6), 2025. e-Pub 2025. PMID: 40460677.
17. He LJ, Wang Y, Curry JL, Ning J, Aung PP, Nagarajan P, Prieto VG, Torres-Cabala CA, Cho WC. TROP2 is highly expressed in cutaneous squamous cell carcinomas and a subset of adnexal carcinomas: A potential therapeutic target with TROP2-directed antibody drug conjugates. Hum Pathol 160:105853, 2025. e-Pub 2025. PMID: 40523445.
18. Li Y, Lai D, Li R, Chen H, Huang X, Ning J. A Biomarker Signature-Guided Clinical Trial Design for Precision Medicine. Stat Med 44(10-12):e70103, 2025. e-Pub 2025. PMID: 40405471.
19. Daver N, Senapati J, Kantarjian H, Wang B, Reville P, Loghavi S, Yilmaz M, DiNardo C, Kadia T, Yassouf M, Maiti A, Arora S, Montalban-Bravo G, Tang G, Gautam, Borthakur, Sasaki K, Pemmaraju N, Alvarez J, Graciela, Nogueras-González, Ning J, Issa G, Konopleva M, Andreeff M, Ravandi F, Garcia-Manero G, Abbas AH. Azacitidine, Venetoclax and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase 1b/2 Study and Correlative Analysis. Clinical Cancer Research, 2025. e-Pub 2025.
20. Swaminathan M, DiNardo CD, Maiti A, Pemmaraju N, Ohanian M, Daver NG, Garcia-Manero G, Issa GC, Borthakur G, Ravandi F, Montalban-Bravo G, Kadia TM, Alvarado Y, Jabbour EJ, Short NJ, Wierda WG, Jain N, Kornblau SM, Masarova L, Pierce SA, Qiao W, Ning J, Kantarjian H, Konopleva MY. Venetoclax in combination with 10-day decitabine in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome: long term follow-up of a phase 2 trial. Blood Cancer Journal 15(1):52, 2025. e-Pub 2025.
21. Qin J, Piao J, Ning J, Shen Y. Conformal predictive intervals in survival analysis: a resampling approach. Biometrics 81(2), 2025. e-Pub 2025. PMID: 40417913.
22. Zhu H, Zhang L, Ning J, Wang L. Testing Hypotheses of Covariate-Adaptive Randomized Clinical Trials with Time-to-event Outcomes under the AFT model. Statistics Sinica 35:1051-1067, 2025. e-Pub 2025.
23. Abts T, Vu T, Perrier ND, Wang Y, Ning J, Debnam JM. Detection Rate and Concordance of 4D-MDCT, US, and Tc99m MIBI Imaging in the Detection of Ectopic and Intrathyroidal Parathyroid Adenomas. World J Surg 49(4):957-963, 2025. e-Pub 2025. PMID: 39988640.
24. Dong W, Fujii T, Ning J, Iwase T, Qin J, Ueno NT, Shen Y. Reassessing estrogen receptor expression thresholds for breast cancer prognosis in HER2-negative patients using shape restricted modeling. Sci Rep 15(1):5590, 2025. e-Pub 2025. PMID: 39955419.
25. Rong R, Ning J, Zhu H. Regression Modeling of Cumulative Incidence Function for Left-Truncated Right-Censored Competing Risks Data: A Modified Pseudo-observation Approach. Communications in Statistics – Theory and Methods, 2025. e-Pub 2025. PMID: 40895373.
26. Tang C, Tan G, Teymur A, Guo J, Haces-Garcia A, Zhu W, Williams R, Ning J, Saxena R, Wu T. A serum biomarker panel and miniarray detection system for tracking disease activity and flare risk in lupus nephritis. Front Immunol 16:1541907, 2025. e-Pub 2025. PMID: 40375995.
27. Li W, Li R, Feng Z, Ning J. Dynamic and Concordance-assisted Learning for Risk Stratification with Application to Alzheimer's Disease. Biostatistics 26(1), 2025. e-Pub 2025. PMID: 39255368.
28. Huang, X, Wang, J, Ning, J. The Win Ratio Approach in Bayesian Monitoring for Two-Arm Phase II Clinical Trial Designs With Multiple Time-To-Event Endpoints. Statistics in Medicine 43(30):5922-5934, 2024. e-Pub 2024. PMID: 39582325.
29. Zhang, R, Shang, Y, Cioccio, J, Rakszawski, KL, Nickolich, M, Ehmann, WC, Inoue, Y, Naik, S, Rybka, W, Zheng, H, Mierski, J, Silar, B, Liao, J, Greiner, R, Brown, VI, Claxton, DF, Ning, J, Zhou, S, Mineishi, S, Minagawa, K, Shike, H. Sensitivity and Specificity of Chimerism Tests in Predicting Leukemia Relapse Using Increasing Mixed Chimerism. Journal of Molecular Diagnostics 26(12):1159-1170, 2024. e-Pub 2024. PMID: 39603755.
30. Chen, Z, Shen, Y, Qin, J, Ning, J. Likelihood adaptively incorporated external aggregate information with uncertainty for survival data. Biometrics 80(4), 2024. e-Pub 2024. PMID: 39468742.
31. Singal AG, Parikh ND, Shetty K, Han SH, Xie C, Ning J, Rinaudo JA, Arvind A, Lok AS, Kanwal F, Cancer Investigators TL. Natural History of Indeterminate Liver Nodules in Patients With Advanced Liver Disease: A Multicenter Retrospective Cohort Study. Am J Gastroenterol 119(11):2251-2258, 2024. e-Pub 2024. PMID: 38686922.
32. Wang J, Jiang X, Ning J. Evaluating dynamic and predictive discrimination for recurrent event models: use of a time-dependent C-index. Biostatistics 25(4):1140-1155, 2024. e-Pub 2024. PMID: 37952117.
33. El-Serag, H, Thrift, AP, Duong, H, Ning, J, Khaderi, SA, Singal, AG, Asrani, SK, Marrero, JA, Powell, H, Rizwan, K, Najjar, O, Amos, CI, Luster, M, Al-Sarraj, A, Salem, E, Scheurer, ME, Chhatwal, J, Kaochar, S, Kanwal, F. Serum levels of total bile acids are associated with an increased risk of HCC in patients with cirrhosis. Hepatology Communications 8(11), 2024. e-Pub 2024. PMID: 39652379.
34. Zhao J, Williams MD, Hernandez M, Kuang G, Goldberg H, Fan J, Ning J, Ferrarotto R, Esmaeli B. Prognostic Impact of Notch1 Intracellular Domain, P63, and c-MYC in Lacrimal Gland Adenoid Cystic Carcinoma. Invest Ophthalmol Vis Sci 65(11):4, 2024. e-Pub 2024. PMID: 39230995.
35. Jiang X, Li W, Wang K, Li R, Ning J. Analyzing Heterogeneity in Biomarker Discriminative Performance through Partial Time-Dependent Receiver Operating Characteristic Curve Modeling. Stat Methods Med Res 33(8):9622802241262521, 2024. e-Pub 2024. PMID: 39053568.
36. Kim MJ, Liu YA, Wang Y, Ning J, Cho WC. TRPS1 Expression Is Frequently Seen in a Subset of Cutaneous Mesenchymal Neoplasms and Tumors of Uncertain Differentiation: A Potential Diagnostic Pitfall. Dermatopathology (Basel) 11(3):200-208, 2024. e-Pub 2024. PMID: 39051323.
37. Goldberg H, Jiang X, Fan J, Zhao J, Ning J, Williams M, Frank S, Moreno A, Gunn B, Ferrarotto R, Esmaeli B. Lacrimal Gland Adenocarcinoma Clinicopathologic Features and Outcomes Compared With Those of Lacrimal Gland Adenoid Cystic Carcinoma. Ophthalmic Plast Reconstr Surg 40(4):419-425, 2024. e-Pub 2024. PMID: 38319188.
38. Li W, Wang Q, Ning J, Zhang J, Li Z, Savitz SI, Tahanan A, Rahbar MH. Enhancing Long-term Survival Prediction with Two Short-term Events: Landmarking with A Flexible Varying Coefficient Model. Stat Med 43(13):2607-2621, 2024. e-Pub 2024. PMID: 38664221.
39. El-Serag H, Kanwal F, Ning J, Powell H, Khaderi S, Singal AG, Asrani S, Marrero JA, Amos CI, Thrift AP, Luster M, Alsarraj A, Olivares L, Skapura D, Deng J, Salem E, Najjar O, Yu X, Duong H, Scheurer ME, Ballantyne CM, Kaochar S. Serum Biomarker Signature Is Predictive of the Risk of Hepatocellular Cancer in Patients with Cirrhosis. Gut 73(6):1000-1007, 2024. e-Pub 2024. PMID: 38365278.
40. Gleber-Netto, FO, Nagarajan, P, Sagiv, O, Pickering, CR, Gross, N, Ning, J, Yeshi, MM, Mitku, Y, Tetzlaff, M, Esmaeli, B. Histologic and Genomic Analysis of Conjunctival SCC in African and American Cohorts Reveal UV Light and HPV Signatures and High Tumor Mutation Burden. Investigative ophthalmology & visual science 65(4):24, 2024. e-Pub 2024. PMID: 38597722.
41. Jiang X, Li W, Li R, Ning J. Addressing Subject Heterogeneity in Time-dependent Discrimination for Biomarker Evaluation. Stat Med 43(7):1341-1353, 2024. e-Pub 2024. PMID: 38287471.
42. Liu YA, Aung PP, Wang Y, Ning J, Nagarajan P, Curry JL, Torres-Cabala CA, Ivan D, Prieto VG, Ding Q, Cho WC. TRPS1 expression in non-melanocytic cutaneous neoplasms: an immunohistochemical analysis of 200 cases. J Pathol Transl Med 58(2):72-80, 2024. e-Pub 2024. PMID: 38389280.
43. Li W, Rahbar MH, Savitz SI, Zhang J, Kim Lundin S, Tahanan A, Ning J. Regression analysis of multivariate recurrent event data allowing time-varying dependence with application to stroke registry data. Stat Methods Med Res 33(2):9622802231226330, 2024. e-Pub 2024. PMID: 38263734.
44. Zhao J, Jiang X, Hanna E, Su SY, Moreno A, Gunn B, Frank SJ, Ferrarotto R, Ning J, Esmaeli B. Orbital and Periocular Complications in Patients with Sinonasal Tumors with Orbital Invasion. Br J Ophthalmol 108(3):465-470, 2024. e-Pub 2024. PMID: 36707226.
45. Li R, Wang J, Zhang C, Squires JE, Belle SH, Ning J, Cai J, Squires RH. Improved mortality prediction for pediatric acute liver failure using dynamic prediction strategy. J Pediatr Gastroenterol Nutr 78(2):320-327, 2024. e-Pub 2024. PMID: 38374548.
46. Wang S, Ning J, Xu Y, Shih Y, She Y, and Li L L. Longitudinal Varying Coefficient Single-index Model with Censored Covariates. Biometrics 80(1), 2024. e-Pub 2024. PMID: 38364803.
47. Zhang C, Ning J, Cai J, Squires JE, Belle SH, Li R. Dynamic Risk Score Modeling for Multiple Longitudinal Risk Factors and Survival. Comput Stat Data Anal 189, 2024. e-Pub 2024. PMID: 37720873.
48. Li Z, Shen Y, Ning J. Accommodating Time-Varying Heterogeneity in Risk Estimation under the Cox Model: a Transfer Learning Approach. J Am Stat Assoc 118(544):2276-2287, 2023. e-Pub 2023. PMID: 38505403.
49. Ding M, Li R, Qin J, Ning J. A Double Robust Test for High-Dimensional Gene Co-expression Networks Conditioning on Clinical Information. Biometrics 79(4):3227-3238, 2023. e-Pub 2023. PMID: 37312587.
50. Kanwal F, Khaderi S, Singal AG, Marrero JA, Asrani SK, Amos CI, Thrift AP, Kramer JR, Yu X, Cao Y, Luster M, Al-Sarraj A, Ning J, El-Serag HB. Risk Stratification Model for Hepatocellular Cancer in Patients with Cirrhosis. Clin Gastroenterol Hepatol 21(13):3296-3304.e3, 2023. e-Pub 2023. PMID: 37390101.
51. Zhao Z, Frank SJ, Ning J, Zhao J, Jiang X, Wang XA, Schefler AC, Hanna E, Moreno A, Gunn B, Ferrarotto R, Esmaeli B. Visual outcome and ocular complications in patients with lacrimal gland carcinoma after eye-sparing surgery and adjuvant radiation therapy. Br J Ophthalmol 107(12):1914-1919, 2023. e-Pub 2023. PMID: 36229179.
52. Jeske AH, Anderson AE, Do KA, Ning J, Ma J, Bruera E. Patterns of opioid use among Texas dental practitioners during the COVID-19 pandemic. J Opioid Manag 19(6):523-532, 2023. e-Pub 2023. PMID: 38189194.
53. Dong W, Fujii T, Ning J, Iwase T, Qin J, Ueno NT, Shen Y. Reassessing Estrogen Receptor Expression Thresholds for Breast Cancer Prognosis in HER2-negative Patients Using Shape Restricted Modeling. Res Sq, 2023. e-Pub 2023. PMID: 37961619.
54. Pak D, Ning J, Kryscio RJ, Shen Y. Evaluation of the natural history of disease by combining incident and prevalent cohorts: application to the Nun Study. Lifetime Data Anal 29(4):1-17, 2023. e-Pub 2023. PMID: 37210470.
55. Cho WC, Li W, Gu J, Wang WL, Ning J, Sfamenos S, Gill P, Nagarajan P, Curry JL, Lazar AJ, Prieto VG, Torres-Cabala CA, Aung PP. Telomerase reverse transcriptase (TERT) immunohistochemical expression is sensitive but not specific for TERT gene amplification in acral melanoma. J Cutan Pathol 50(9):845-851, 2023. e-Pub 2023. PMID: 37400233.
56. Law T, Piotrowski MJ, Ning J, Jiang X, Ding Q, Sahin AA. Trichorhinophalangeal Syndrome Type 1 (TRPS1) Expression in Male Breast Carcinoma. Hum Pathol 138:62-67, 2023. e-Pub 2023. PMID: 37331526.
57. Wang S, Ning J, Xu Y, Shih TYC, Shen Y, Li L. An extension of estimating equations to model longitudinal medical cost trajectory with Medicare claims data linked to SEER cancer registry. Ann Appl Stat 17(1):881-899, 2023. e-Pub 2023.
58. Zhang J, Ning J, Li R. Evaluating Dynamic Discrimination Performance of Risk Prediction Models for Survival Outcomes. Stat Biosci 15(2):353-371, 2023. e-Pub 2023. PMID: 37691982.
59. Nguyen D, Kantarjian HM, Short NJ, Qiao W, Ning J, Cuglievan B, Daver NG, DiNardo CD, Jabbour EJ, Kadia TM, Borthakur G, Garcia-Manero G, Konopleva MY, Andreeff M, Ravandi-Kashani F, Sasaki K, Issa GC. Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation. Cancer 129(12):1856-1865, 2023. e-Pub 2023. PMID: 36892949.
60. Haddad FG, Kantarjian HM, Bidikian A, Jabbour EJ, Short NJ, Ning J, Xiao L, Pemmaraju N, DiNardo CD, Kadia TM, Marx KR, Garcia-Manero G, Ravandi F, Sasaki K, Issa GC. Association Between Bariatric Surgery and Outcomes in Chronic Myeloid Leukemia. Cancer 129(12):1866-1872, 2023. e-Pub 2023. PMID: 36882573.
61. Li W, Li R, Yan Q, Feng Z, Ning J. Conditional Concordance-assisted Learning Under Matched Case-control Design for Combining Biomarkers for Population Screening. Stat Med 42(9):1398-1411, 2023. e-Pub 2023. PMID: 36733187.
62. Nguyen NH, Shin SJ, Dodd-Eaton EB, Ning J, Wang W. Personalized Risk Prediction for Cancer Survivors: A Bayesian Semi-parametric Recurrent Event Model with Competing Outcomes. bioRxiv, 2023. e-Pub 2023. PMID: 36909464.
63. Wang S, Ning J, Xu Y, Shih YT, Shen YU, Li L. An extension of estimating equations to model longitudinal medical cost trajectory with Medicare claims data linked to SEER cancer registry. Ann Appl Stat 17(1):881-899, 2023. e-Pub 2023. PMID: 40342805.
64. Yennurajalingam S, Konopleva M, Carmack CL, Dinardo CD, Gaffney M, Michener HK, Lu Z, Stanton P, Ning J, Qiao W, Bruera E. Treatment of Cancer-related-Fatigue in Acute Hematological Malignancies: Results of a Feasibility Study of using Cognitive Behavioral Therapy. J Pain Symptom Manage 65(3):e189-e197, 2023. e-Pub 2023. PMID: 36384181.
65. Kanwal F, Khaderi S, Singal AG, Marrero JA, Loo N, Asrani SK, Amos CI, Thrift AP, Gu X, Luster M, Al-Sarraj A, Ning J, El-Serag HB. Risk Factors for Hepatocellular Cancer in Contemporary Cohorts of Patients with Cirrhosis. Hepatology 77(3):997-1005, 2023. e-Pub 2023. PMID: 35229329.
66. Thrift AP, Kanwal F, Liu Y, Khaderi S, Singal AG, Marrero JA, Loo N, Asrani SK, Luster M, Al-Sarraj A, Ning J, Tsavachidis S, Gu X, Amos CI, El-Serag HB. Risk stratification for hepatocellular cancer among patients with cirrhosis using a hepatic fat polygenic risk score. PLoS One 18(2):e0282309, 2023. e-Pub 2023. PMID: 36854015.
67. Shen Y, Ning J, Lin HY, Shaitelman SF, Kuerer HM, Bedrosian I. Effectiveness Without Efficacy: Cautionary Tale from a Landmark Breast Cancer Randomized Controlled Trial. J Cancer 14(2):193-199, 2023. e-Pub 2023. PMID: 36741254.
68. Liu X, Ning J, He X, Tilley BC, Li R. Semiparametric regression modeling of the global percentile outcome. J Stat Plan Inference 222:149-159, 2023. e-Pub 2023. PMID: 36467464.
69. Weissferdt A, Sepesi B, Ning J, Hermsen M, Ferrarotto R, Glisson B, Hanna E, Bell D. Optimal Combination of Neuroendocrine Markers for the Detection of High-Grade Neuroendocrine Tumors of the Sinonasal Tract and Lung. Curr Oncol Rep 25(1):1-10, 2023. e-Pub 2023. PMID: 36422794.
70. Zhang C, Ning J, Belle SH, Squires RH, Cai J, Li R. Assessing Predictive Discrimination Performance of Biomarkers in the Presence of Treatment-induced Dependent Censoring. J R Stat Soc Ser C Appl Stat 71(5):1137-1157, 2022. e-Pub 2022. PMID: 36466585.
71. Cortés Martínez J, Pak D, Abelenda-Alonso G, Langohr K, Ning J, Rombauts A, Colom M, Shen Y, Gómez Melis G. SARS-Cov-2 incubation period according to vaccination status during the fifth COVID-19 wave in a tertiary-care center in Spain: a cohort study. BMC Infect Dis 22(1):1-7, 2022. e-Pub 2022. PMID: 36352359.
72. Short NJ, Borthakur G, Pemmaraju N, Dinardo CD, Kadia TM, Jabbour E, Konopleva M, Macaron W, Ning J, Ma J, Pierce S, Alvarado Y, Sasaki K, Takahashi K, Estrov Z, Masarova L, Issa GC, Montalban-Bravo G, Andreeff M, Burger JA, Miller D, Alexander L, Naing A, Garcia-Manero G, Ravandi F, Daver N. A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. Leuk Lymphoma 63(9):1-10, 2022. e-Pub 2022. PMID: 35442137.
73. Gao X, Shen W, Ning J, Feng Z, Hu J. Addressing patient heterogeneity in disease predictive model development. Biometrics 78(3):1045-1055, 2022. e-Pub 2022. PMID: 34184256.
74. Rong R, Ning J, Zhu H. Regression modeling of restricted mean survival time for left-truncated right-censored data. Stat Med 41(16):3003-3021, 2022. e-Pub 2022. PMID: 35708238.
75. Marks-Anglin A, Luo C, Piao J, Gibbons MBC, Schmid CH, Ning J, Chen Y. EMBRACE: an EM-based Bias Reduction Approach through Copas-Model Estimation for Quantifying the evidence of selective publishing in network meta-analysis. Biometrics 78(2):754-765, 2022. e-Pub 2022. PMID: 33559881.
76. Tang C, Tan G, Teymur A, Guo J, Haces-Garcia A, Zhu W, Williams R, Ning J, Saxena R, MD PhD TWMIEBFR. A Serum Biomarker Panel and Miniarray Detection System for Tracking Disease Activity and Flare Risk in Lupus Nephritis. Frontiers in Immunology 16, 2022. e-Pub 2022. PMID: 40375995.
77. Ning J, Pak D, Zhu H, Qin J. Conditional Independence Test of Failure and Truncation Times: Essential Tool for Method Selection. Comput Stat Data Anal 168, 2022. e-Pub 2022. PMID: 34898770.
78. Li R, Ning J, Feng Z. Estimation and Inference of Predictive Discrimination for Survival Outcome Risk Prediction Models. Lifetime Data Anal 28(2):219-240, 2022. e-Pub 2022. PMID: 35061146.
79. Zhu H, Lan Y, Ning J, Shen Y. Semiparametric copula-based regression modeling of semicompeting risks data. Commun Stat Theory Methods 51(22):7830-7845, 2022. e-Pub 2022. PMID: 36353187.
80. Venugopal S, Maiti A, DiNardo CD, Qiao W, Ning J, Loghavi S, Daver NG, Kadia TM, Rausch CR, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Ravandi F, Kantarjian HM, Konopleva MY. Prognostic Impact of Conventional Cytogenetics in Acute Myeloid Leukemia Treated with Venetoclax and Decitabine. Leuk Lymphoma 62(14):1-5, 2021. e-Pub 2021. PMID: 34474640.
81. El-Hadad C, Koka K, Dong W, Do T, Haider M, Ursua JD, Ning J, Debnam JM, Esmaeli B. Multidisciplinary Management of Orbital Metastasis and Survival Outcomes. Ophthalmic Plast Reconstr Surg 37(6):541-545, 2021. e-Pub 2021. PMID: 33587417.
82. Maiti A, DiNardo CD, Qiao W, Kadia TM, Jabbour EJ, Rausch CR, Daver NG, Short NJ, Borthakur G, Pemmaraju N, Yilmaz M, Alvarado Y, Montalbano KS, Wade A, Maduike RE, Guerrero JA, Vaughan K, Bivins CA, Pierce S, Ning J, Ravandi F, Kantarjian HM, Konopleva MY. Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis. Cancer 127(22):4213-4220, 2021. e-Pub 2021. PMID: 34343352.
83. Wang J, Ning J, Shete S. Mediation model with a categorical exposure and a censored mediator with application to a genetic study. PLoS One 16(10):e0257628, 2021. e-Pub 2021. PMID: 34637449.
84. Zhang J, Ning J, Huang X, Li R. On the Time-varying Predictive Performance of Longitudinal Biomarkers: Measure and Estimation. Stat Med 40(23):5065-5077, 2021. e-Pub 2021. PMID: 34159633.
85. Abbas HA, Hao D, Tomczak K, Barrodia P, Im JS, Reville PK, Alaniz Z, Wang W, Wang R, Wang F, Al-Atrash G, Takahashi K, Ning J, Ding M, Beird HC, Mathews JT, Little L, Zhang J, Basu S, Konopleva M, Marques-Piubelli ML, Solis LM, Parra ER, Lu W, Tamegnon A, Garcia-Manero G, Green MR, Sharma P, Allison JP, Kornblau SM, Rai K, Wang L, Daver N, Futreal A. Single cell T cell Landscape and T Cell Receptor Repertoire Profiling of AML in Context of PD-1 Blockade Therapy. Nat Commun 12(1):6071, 2021. e-Pub 2021. PMID: 34663807.
86. Wang J, Ma J, Cai C, Daver N, Ning J. A Bayesian hierarchical monitoring design for phase II cancer clinical trials: incorporating information on response duration into monitoring rules. Stat Med 40(21):4629-4639, 2021. e-Pub 2021. PMID: 34101217.
87. Qin J, Deng G, Ning J, Yuan A, Shen Y. Estrogen receptor expression on breast cancer patients' survival under shape restricted Cox regression model. Ann Appl Stat 15(3):1291-1307, 2021. e-Pub 2021. PMID: 34745408.
88. Yuan A, Piao J, Ning J, Qin J. Semiparametric isotonic regression modelling and estimation for group testing data. Can J Stat 49(3):659-677, 2021. e-Pub 2021. PMID: 34690407.
89. Chen Z, Ning J, Shen Y, Qin J. Combining primary cohort data with external aggregate information without assuming comparability. Biometrics 77(3):1024-1036, 2021. e-Pub 2021. PMID: 32827153.
90. Ding M, Ning J, Li R. Evaluation of competing risks prediction models using polytomous discrimination index. Can J Stat 49(3):731-753, 2021. e-Pub 2021. PMID: 34707327.
91. Issa GC, Zarka J, Sasaki K, Qiao W, Pak D, Ning J, Short NJ, Haddad F, Tang Z, Patel KP, Cuglievan B, Daver N, DiNardo CD, Jabbour E, Kadia T, Borthakur G, Garcia-Manero G, Konopleva M, Andreeff M, Kantarjian HM, Ravandi F. Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. Blood Cancer J 11(9):162, 2021. e-Pub 2021. PMID: 34588432.
92. Jain N, Maiti A, Ravandi F, Konopleva M, Daver N, Kadia T, Pemmaraju N, Short N, Kebriaei P, Ning J, Cortes J, Jabbour E, Kantarjian H. Inotuzumab Ozogamicin with Bosutinib for Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Lymphoid Blast Phase of Chronic Myeloid Leukemia. Am J Hematol 96(8):1000-1007, 2021. e-Pub 2021. PMID: 33991360.
93. Rausch CR, DiNardo CD, Maiti A, Jammal NJ, Kadia TM, Marx KR, Borthakur G, Savoy JM, Pemmaraju N, DiPippo AJ, Daver NG, Chew SM, Sasaki K, Issa GC, Short NJ, Takahashi K, Ohanian MN, Ning J, Xiao L, Alvarado Y, Kontoyiannis DP, Ravandi F, Kantarjian HM, Konopleva MY. Duration of Cytopenias with Concomitant Venetoclax and Azole Antifungals in Acute Myeloid Leukemia. Cancer 127(14):2489-2499, 2021. e-Pub 2021. PMID: 33793970.
94. Ford JR, Rubin ML, Frank SJ, Ning J, Debnam JM, Bell D, El-Naggar A, Ferrarotto R, Esmaeli B. Prognostic Factors for Local Recurrence and Survival and Impact of Local Treatments on Survival in Lacrimal Gland Carcinoma. Br J Ophthalmol 105(6):768-774, 2021. e-Pub 2021. PMID: 32680839.
95. El-Hadad C, Rubin ML, Nagarajan P, Ford JR, Xu S, Ning J, Esmaeli B. Prognostic Factors for Orbital Exenteration, Local Recurrence, Metastasis, and Death From Disease in Conjunctival Squamous Cell Carcinoma. Ophthalmic Plast Reconstr Surg 37(3):262-268, 2021. e-Pub 2021. PMID: 33009325.
96. Park Y, Yuan Y, Ning J, Liu S, Feng Z. Hybrid design evaluating new biomarkers when there is an existing screening test. Stat Med 40(8):2037-2054, 2021. e-Pub 2021. PMID: 33540472.
97. Maiti A, DiNardo CD, Wang SA, Jorgensen J, Kadia TM, Daver NG, Short NJ, Yilmaz M, Pemmaraju N, Borthakur G, Bose P, Issa GC, Ferrajoli A, Jabbour EJ, Jain N, Garcia-Manero G, Ohanian M, Takahashi K, Montalban-Bravo G, Masarova L, Burger JA, Thompson PA, Verstovsek S, Sasaki K, Andreeff M, Rausch CR, Montalbano KS, Pierce S, Qiao W, Ning J, Kantarjian HM, Konopleva MY, Ravandi F. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv 5(7):1876-1883, 2021. e-Pub 2021. PMID: 33792630.
98. Dalle IA, Paranal R, Zarka J, Paul S, Sasaki K, Li W, Ning J, Short NJ, Ohanian M, Cortes JE, Jabbour EJ, Issa GC. Impact of luteinizing hormone suppression on hematopoietic recovery after intensive chemotherapy in patients with leukemia. Haematologica 106(4):0, 2021. e-Pub 2021. PMID: 33297667.
99. Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur G, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Kadia TM, Takahashi K, Yilmaz M, Jain N, Kornblau S, Montalban Bravo G, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabbour EJ, Masarova L, Thompson PA, Wang S, Konoplev S, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica 106(3):894-898, 2021. e-Pub 2021. PMID: 32499238.
100. Diao S, Nichols ED, DiNardo C, Konopleva M, Ning J, Qiao W, Maiti A, DiPippo AJ. Incidence of Tumor Lysis Syndrome in Patients with Acute Myeloid Leukemia Undergoing Low-Intensity Induction with Venetoclax. Am J Hematol 96(3):E65-E68, 2021. e-Pub 2021. PMID: 33259075.
101. Maiti A, Qiao W, Sasaki K, Ravandi F, Kadia TM, Jabbour EJ, Daver NG, Borthakur G, Garcia-Manero G, Pierce SA, Montalbano KS, Pemmaraju N, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Takahashi K, Yilmaz M, Jain N, Kornblau SM, Andreeff M, Bose P, Ferrajoli A, Issa GC, Masarova L, Thompson PA, Rausch CR, Ning J, Kantarjian HM, DiNardo CD, Konopleva MY. Venetoclax with Decitabine Versus Intensive Chemotherapy in Acute Myeloid Leukemia: A Propensity Score Matched Analysis Stratified by Risk of Treatment-related Mortality. Am J Hematol 96(3):282-291, 2021. e-Pub 2021. PMID: 33264443.
102. Pak D, Liu J, Ning J, Gómez G, Shen Y. Analyzing left-truncated and right-censored infectious disease cohort data with interval-censored infection onset. Stat Med 40(2):287-298, 2021. e-Pub 2021. PMID: 33086432.
103. Zhao NO, Daewoo P, El-Hadad C, Debnam JM, Ning J, Esmaeli B. Characteristics and Survival Outcomes of Second Primary Cancers in Long-term Retinoblastoma Survivors. Asia Pac J Ophthalmol (Phila) 10(4):366-372, 2021. e-Pub 2021. PMID: 33481394.
104. Xia F, George SL, Ning J, Li L, Huang X. A Signature Enrichment Design with Bayesian Adaptive Randomization. J Appl Stat 48(6):1-20, 2021. e-Pub 2021. PMID: 34024982.
105. Chen J, Mi X, Ning J, He X, Hu J. A tail-based test to detect differential expression in RNA-sequencing data. Stat Methods Med Res 30(1):261-276, 2021. e-Pub 2021. PMID: 32867604.
106. Smith DL, Debeb BG, Diagaradjane P, Larson R, Kumar S, Ning J, Lacerda L, Li L, Woodward WA. Prophylactic cranial irradiation reduces the incidence of brain metastasis in a mouse model of metastatic, HER2-positive breast cancer. Genes Cancer 12:28-38, 2021. e-Pub 2021. PMID: 33884104.
107. Ning J, Cai C, Chen Y, Huang X, Wang MC. Semiparametric Modelling and Estimation of Covariate-Adjusted Dependence between Bivariate Recurrent Events. Biometrics 76(4):1229-1239, 2020. e-Pub 2020. PMID: 31994170.
108. Short NJ, Rafei H, Daver N, Hwang H, Ning J, Jorgensen JL, Kadia TM, DiNardo CD, Wang SA, Jabbour E, Popat U, Oran B, Cortes J, Konopleva M, Yilmaz M, Issa GC, Kantarjian H, Ravandi F. Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML. Blood Adv 4(24):6117-6126, 2020. e-Pub 2020. PMID: 33351107.
109. Issa GC, Kantarjian HM, Xiao L, Ning J, Alvarado Y, Borthakur G, Daver N, DiNardo CD, Jabbour E, Bose P, Jain N, Kadia TM, Naqvi K, Pemmaraju N, Takahashi K, Verstovsek S, Andreeff M, Kornblau SM, Estrov Z, Ferrajoli A, Garcia-Manero G, Ohanian M, Wierda WG, Ravandi F, Cortes JE. Phase II Trial of CPX-351 in Patients with Acute Myeloid Leukemia at High Risk for Induction Mortality. Leukemia 34(11):2914-2924, 2020. e-Pub 2020. PMID: 32546726.
110. Tetzlaff MT, Adhikari C, Lo S, Rawson RV, Amaria RN, Menzies AM, Wilmott JS, Ferguson PM, Ross MI, Spillane AJ, Vu KA, Ma J, Ning J, Haydu L, Saw RPM, Wargo JA, Tawbi HA, Gershenwald JE, Long GV, Davies MA, Scolyer RA. Histopathological features of complete pathological response predict recurrence free survival following neoadjuvant targeted therapy for metastatic melanoma. Ann Oncol 31(11):1569-1579, 2020. e-Pub 2020. PMID: 32739408.
111. Farah M, Reuben A, Spassova I, Yang RK, Kubat L, Nagarajan P, Ning J, Li W, Aung PP, Curry JL, Torres-Cabala CA, Hudgens CW, Ugurel S, Schadendorf D, Gumbs C, Little LD, Futreal A, Wistuba II, Prieto VG, Wang L, Wong MK, Wargo JA, Becker JC, Tetzlaff MT. T-Cell Repertoire in Combination with T-Cell Density Predicts Clinical Outcomes in Patients with Merkel Cell Carcinoma. J Invest Dermatol 140(11):2146-2156.e4, 2020. e-Pub 2020. PMID: 32304704.
112. Short NJ, Montalban-Bravo G, Hwang H, Ning J, Franquiz MJ, Kanagal-Shamanna R, Patel KP, DiNardo CD, Ravandi F, Garcia-Manero G, Takahashi K, Konopleva M, Daver N, Issa GC, Andreeff M, Kantarjian H, Kadia TM. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. Blood Adv 4(22):5681-5689, 2020. e-Pub 2020. PMID: 33211826.
113. DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol 7(10):e724-e736, 2020. e-Pub 2020. PMID: 32896301.
114. Pak D, Klaus Langohr K, Ning J, Martínez JC, Melis GG, Shen Y. Modeling the coronavirus disease 2019 incubation period: impact on quarantine policy. Mathematics 8(9):1631, 2020. e-Pub 2020.
115. Li W, Li R, Feng Z, Ning J. Semiparametric Isotonic Regression Analysis for Risk Assessment under Nested Case-Control and Case-Cohort Designs. Stat Methods Med Res 29(8):2328-2343, 2020. e-Pub 2020. PMID: 31868119.
116. Blessing AM, Santiago-O'Farrill JM, Mao W, Pang L, Ning J, Pak D, Bollu LR, Rask P, Iles L, Yang H, Tran S, Elmir E, Bartholomeusz G, Langley R, Lu Z, Bast RC. Elimination of dormant, autophagic ovarian cancer cells and xenografts through enhanced sensitivity to anaplastic lymphoma kinase inhibition. Cancer 126(15):3579-3592, 2020. e-Pub 2020. PMID: 32484926.
117. Shin SJ, Li J, Ning J, Bojadzieva J, Strong LC, Wang W. Bayesian estimation of a semiparametric recurrent event model with applications to the penetrance estimation of multiple primary cancers in Li-Fraumeni Syndrome. Biostatistics 21(3):467-482, 2020. e-Pub 2020. PMID: 30445420.
118. Xu S, Moss TJ, Laura Rubin M, Ning J, Eterovic K, Yu H, Jia R, Fan X, Tetzlaff MT, Esmaeli B. Whole-exome sequencing for ocular adnexal sebaceous carcinoma suggests PCDH15 as a novel mutation associated with metastasis. Mod Pathol 33(7):1256-1263, 2020. e-Pub 2020. PMID: 31937901.
119. Lee CH, Zhou H, Ning J, Liu DD, Shen Y. CoxPhLb: An R package for analyzing length biased data under Cox model. R Journal 12(1):118–130, 2020. e-Pub 2020. PMID: 33133648.
120. Lachowiez CA, Loghavi S, Kadia TM, Daver N, Borthakur G, Pemmaraju N, Naqvi K, Alvarado Y, Yilmaz M, Short N, Ohanian M, Pierce SR, Patel KP, Qiao W, Ning J, Sasaki K, Takahashi K, Jabbour E, Andreeff M, Ravandi F, Kantarjian HM, Konopleva M, DiNardo CD. Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. Blood Adv 4(7):1311-1320, 2020. e-Pub 2020. PMID: 32251497.
121. Sa HS, Rubin ML, Ning J, Li W, Tetzlaff MT, McGovern SL, Paulino AC, Herzog CE, Gill JB, Esmaeli B. Association of T and N Categories of the American Joint Commission on Cancer, 8th Edition, With Metastasis and Survival in Patients With Orbital Sarcoma. JAMA Ophthalmol 138(4):374-381, 2020. e-Pub 2020. PMID: 32105303.
122. Nagarajan P, Piao J, Ning J, Noordenbos LE, Curry JL, Torres-Cabala CA, Diwan AH, Ivan D, Aung PP, Ross MI, Royal RE, Wargo JA, Wang WL, Samdani R, Lazar AJ, Rashid A, Davies MA, Prieto VG, Gershenwald JE, Tetzlaff MT. Prognostic Model for Patient Survival in Primary Anorectal Mucosal Melanoma: Stage at Presentation Determines Relevance of Histopathologic Features. Mod Pathol 33(3):496-513, 2020. e-Pub 2020. PMID: 31383963.
123. Bell D, Ferrarotto R, Liang L, Goepfert RP, Li J, Ning J, Broaddus R, Weber RS, El-Naggar AK. Pan-Trk immunohistochemistry reliably identifies ETV6-NTRK3 fusion in secretory carcinoma of the salivary gland. Virchows Arch 476(2):295-305, 2020. e-Pub 2020. PMID: 31423558.
124. Yang WL, Lu Z, Guo J, Fellman BM, Ning J, Lu KH, Menon U, Kobayashi M, Hanash SM, Celestino J, Skates SJ, Bast RC. Human epididymis protein 4 antigen-autoantibody complexes complement cancer antigen 125 for detecting early-stage ovarian cancer. Cancer 126(4):725-736, 2020. e-Pub 2020. PMID: 31714597.
125. Shin SJ, Dodd-Eaton EB, Gao F, Bojadzieva J, Chen J, Kong X, Amos CI, Ning J, Strong LC, Wang W. Penetrance estimates over time to first and second primary cancer diagnosis in families with Li-Fraumeni syndrome: a single institution perspective. Cancer Res 80(2):347-353, 2020. e-Pub 2020. PMID: 31719099.
126. Esmaeli B, Rubin ML, Xu S, Goepfert RP, Curry JL, Prieto VG, Ning J, Tetzlaff MT. Greater Tumor Thickness, Ulceration, and Positive Sentinel Lymph Node Are Associated with Worse Prognosis in Patients with Conjunctival Melanoma: Implications for Future AJCC Classifications. Am J Surg Pathol 43(12):1701-1710, 2019. e-Pub 2019. PMID: 31425167.
127. Cai Y, Huang J, Ning J, Lee MT, Rosner B, Chen Y. Two-sample test for correlated data under outcome-dependent sampling with an application to self-reported weight loss data. Stat Med 38(25):4999-5009, 2019. e-Pub 2019. PMID: 31489699.
128. Piao J, Liu Y, Chen Y, Ning J. Copas-Like Selection Model to Correct Publication Bias in Systematic Review of Diagnostic Test Studies. Stat Methods Med Res 28(10-11):962280218791602, 2019. e-Pub 2019. PMID: 30062910.
129. Curry JL, Reuben A, Szczepaniak-Sloane R, Ning J, Milton DR, Lee CH, Hudgens C, George S, Torres-Cabala C, Johnson D, Subramanya S, Wargo JA, Mudaliar K, Wistuba II, Prieto VG, Diab A, Tetzlaff MT. Gene expression profiling of lichenoid dermatitis immune-related adverse event from immune checkpoint inhibitors reveals increased CD14+ and CD16+ monocytes driving an innate immune response. J Cutan Pathol 46(9):627-636, 2019. e-Pub 2019. PMID: 30883858.
130. Shen W, Liu S, Chen Y, Ning J. Regression analysis of longitudinal data with outcome-dependent sampling and informative censoring. Scand Stat Theory Appl 46(3):831-847, 2019. e-Pub 2019. PMID: 32066989.
131. Liu X, Ning J, Cheng Y, Huang X, Li R. A Flexible and Robust Method for Assessing Conditional Association and Conditional Concordance. Stat Med 38(19):3656-3668, 2019. e-Pub 2019. PMID: 31074082.
132. Sa HS, Rubin ML, Xu S, Ning J, Tetzlaff M, Sagiv O, Kandl TJ, Esmaeli B. Prognostic Factors for Local Recurrence, Metastasis, and Survival for Sebaceous Carcinoma of the Eyelid: Observations in 100 Patients. Br J Ophthalmol 103(7):980-984, 2019. e-Pub 2019. PMID: 30131380.
133. Aung PP, Parra ER, Barua S, Sui D, Ning J, Mino B, Ledesma DA, Curry JL, Nagarajan P, Torres-Cabala CA, Efstathiou E, Hoang AG, Wong MK, Wargo JA, Lazar AJ, Rao A, Prieto VG, Wistuba I, Tetzlaff MT. B7-H3 expression in Merkel cell carcinoma-associated endothelial cells correlates with locally aggressive primary tumor features and increased vascular density. Clin Cancer Res 25(11):3455-3467, 2019. e-Pub 2019. PMID: 30808776.
134. Yuan Y, Qiu J, Lin ZT, Li W, Haley C, Mui UN, Ning J, Tyring SK, Wu T. Identification of Novel Autoantibodies Associated with Psoriatic Arthritis. Arthritis Rheumatol 71(6):941-951, 2019. e-Pub 2019. PMID: 30618213.
135. Lee CH, Ning J, Kryscio RJ, Shen Y. Analysis of combined incident and prevalent cohort data under a proportional mean residual life model. Stat Med 38(12):2103-2114, 2019. e-Pub 2019. PMID: 30680767.
136. Nagarajan P, El-Hadad C, Gruschkus SK, Ning J, Hudgens CW, Sagiv O, Gross N, Tetzlaff MT, Esmaeli B. PD-L1/PD-1 Expression, Composition of Tumor-Associated Immune Infiltrate and HPV Status in Conjunctival Squamous Cell Carcinoma. Invest Ophthalmol Vis Sci 60(6):2388-2398, 2019. e-Pub 2019. PMID: 31141610.
137. Williams P, Basu S, Garcia-Manero G, Hourigan CS, Oetjen KA, Cortes JE, Ravandi F, Jabbour EJ, Al-Hamal Z, Konopleva M, Ning J, Xiao L, Hidalgo Lopez J, Kornblau SM, Andreeff M, Flores W, Bueso-Ramos C, Blando J, Galera P, Calvo KR, Al-Atrash G, Allison JP, Kantarjian HM, Sharma P, Daver NG. The distribution of T cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer 125(9):1470-1481, 2019. e-Pub 2019. PMID: 30500073.
138. Xu S, Sagiv O, Rubin ML, Sa HS, Tetzlaff MT, Nagarajan P, Ning J, Esmaeli B. Validation Study of the AJCC Cancer Staging Manual, Eighth Edition, Staging System for Eyelid and Periocular Squamous Cell Carcinoma. JAMA Ophthalmol 137(5):537-542, 2019. e-Pub 2019. PMID: 30869769.
139. Huang X, Liu L, Ning J, Li L, Shen Y. Estimation of the Distribution of Longitudinal Biomarker Trajectories Prior to Disease Progression. Stat Med 38(11):2030-2046, 2019. e-Pub 2019. PMID: 30614014.
140. Guo J, Yang WL, Pak D, Celestino J, Lu KH, Ning J, Lokshin AE, Cheng Z, Lu Z, Bast RC. Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies complement CA125 for Detection of Early Stage Ovarian Cancer. Cancers (Basel) 11(5), 2019. e-Pub 2019. PMID: 31035430.
141. Piao J, Ning J, Shen Y. Semiparametric Model for Bivariate Survival Data Subject to Biased Sampling. J R Stat Soc Series B Stat Methodol 81(2):409-429, 2019. e-Pub 2019. PMID: 31435191.
142. Wang J, Ning J, Shete S. Mediation analysis in a case-control study when the mediator is a censored variable. Stat Med 38(7):1213-1229, 2019. e-Pub 2019. PMID: 30421436.
143. Feng Z, Marrero JA, Khaderi S, Singal AG, Kanwal F, Loo N, Beretta L, Ning J, El-Serag HB. Design of the Texas Hepatocellular Carcinoma Consortium Cohort Study. Am J Gastroenterol 114(3):530-532, 2019. e-Pub 2019. PMID: 30699099.
144. Daver N, Garcia-Manero G, Basu S, Boddu PC, Alfayez M, Cortes JE, Konopleva M, Ravandi-Kashani F, Jabbour E, Kadia T, Nogueras-Gonzalez GM, Ning J, Pemmaraju N, DiNardo CD, Andreeff M, Pierce SA, Gordon T, Kornblau SM, Flores W, Alhamal Z, Bueso-Ramos C, Jorgensen JL, Patel KP, Blando J, Allison JP, Sharma P, Kantarjian H. Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Non-randomized, Open-label, Phase 2 Study. Cancer Discov 9(3):370-383, 2019. e-Pub 2019. PMID: 30409776.
145. Short NJ, Jabbour E, Naqvi K, Patel A, Ning J, Sasaki K, Nogueras-Gonzalez GM, Bose P, Kornblau SM, Takahashi K, Andreeff M, Sanchez-Petitto G, Estrov Z, Dinardo CD, Montalban-Bravo G, Konopleva M, Alvarado Y, Bhalla KN, Fiskus W, Khouri M, Islam R, Kantarjian H, Garcia-Manero G. A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. Am J Hematol 94(1):74-79, 2019. e-Pub 2019. PMID: 30328139.
146. Lee CH, Ning J, Shen Y. Model diagnostics for the proportional hazards model with length-biased data. Lifetime Data Anal 25(1):79-96, 2019. e-Pub 2019. PMID: 29450809.
147. Shen Y, Fujii T, Ueno NT, Tripathy D, Fu N, Zhou H, Ning J, Xiao L. Comparative efficacy of adjuvant trastuzumab-containing chemotherapies for patients with early HER2-positive primary breast cancer: A network meta-analysis. Breast Cancer Res Treat 173(1):1-9, 2019. e-Pub 2019. PMID: 30242579.
148. Ning J, Fouad TM, Lin H, Sahin AA, Lucci A, Woodward WA, Krishnamurthy S, Tripathy D, Ueno NT, Shen Y. The impact of Ki-67 in the context of multidisciplinary care in primary inflammatory breast cancer. J Cancer 10(12):2635-2642, 2019. e-Pub 2019. PMID: 31258771.
149. Tetzlaff MT, Curry JL, Ning J, Sagiv O, Kandl TL, Peng B, Bell D, Routbort M, Hudgens CW, Ivan D, Kim TB, Chen K, Eterovic AK, Shaw K, Prieto VG, Yemelyanova A, Esmaeli B. Distinct biological types of ocular adnexal sebaceous carcinoma: HPV-driven and virus-negative tumors arise through non-overlapping molecular-genetic alterations. Clin Cancer Res 25(4):1280-1290, 2019. e-Pub 2019. PMID: 30420449.
150. Qiao W, Ning J, Huang X. A clinical trial design with covariate-adjusted response-adaptive randomization using superiority confidence of treatments. Stat Biopharm Res 11(4):336-347, 2019. e-Pub 2019. PMID: 34113421.
151. Ger RB, Zhou S, Elgohari B, Elhalawani H, Mackin DM, Meier JG, Nguyen CM, Anderson BM, Gay C, Ning J, Fuller CD, Li H, Howell RM, Layman RR, Mawlawi O, Stafford RJ, Aerts H, Court LE. Radiomics features of the primary tumor fail to improve prediction of overall survival in large cohorts of CT- and PET-imaged head and neck cancer patients. PLoS One 14(9):e0222509, 2019. e-Pub 2019. PMID: 31536526.
152. Khan M, Loree JM, Advani SM, Ning J, Li W, Pereira AAL, Lam M, Raghav K, Morris VK, Broaddus R, Maru D, Overman MJ, Kopetz S. Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics. Clin Colorectal Cancer 17(4):e699-e709, 2018. e-Pub 2018. PMID: 30205948.
153. Jayaprakash P, Ai M, Liu A, Budhani P, Bartkowiak T, Sheng J, Ager C, Nicholas C, Jaiswal AR, Sun Y, Shah K, Balasubramanyam S, Li N, Wang G, Ning J, Zal A, Zal T, Curran MA. Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy. J Clin Invest 128(11):5137-5149, 2018. e-Pub 2018. PMID: 30188869.
154. Ji S, Ning J, Qin J, Follmann D. Conditional Independence Test by Generalized Kendalls tau with Generalized Odds Ratio. Stat Methods Med Res 27(11):3224-3235, 2018. e-Pub 2018. PMID: 29298614.
155. Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, Ravandi-Kashani F, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, Kadia TM, DiNardo CD, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver N. A Phase II Study of Ruxolitinib in Combination with Azacytidine in Patients with Myelofibrosis. Blood 132(16):1664-1674, 2018. e-Pub 2018. PMID: 30185431.
156. Benton CB, Khan M, Sallman D, Nazha A, Nogueras González GM, Piao J, Ning J, Aung F, Al Ali N, Jabbour E, Kadia TM, Borthakur G, Ravandi F, Pierce S, Steensma D, DeZern A, Roboz G, Sekeres M, Andreeff M, Kantarjian H, Komrokji RS, Garcia-Manero G. Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R. Am J Hematol 93(10):1245-1253, 2018. e-Pub 2018. PMID: 30051599.
157. Cao L, Lee CH, Ning J, Handy BC, Wagar EA, Meng QH. Combination of Prostate Cancer Antigen 3 and Prostate-Specific Antigen Improves Diagnostic Accuracy in Men at Risk of Prostate Cancer. Arch Pathol Lab Med 142(9):1106-1112, 2018. e-Pub 2018. PMID: 29547000.
158. Du D, Yuan J, Ma W, Ning J, Weinstein JN, Yuan X, Fuller GN, Liu Y. Clinical Significance of FBXO17 Gene Expression in High-Grade Glioma. BMC Cancer 18(1):773, 2018. e-Pub 2018. PMID: 30064493.
159. Lee CH, Ning J, Shen Y. Analysis of Restricted Mean Survival Time for Length-Biased Data. Biometrics 74(2):575-583, 2018. e-Pub 2018. PMID: 28886217.
160. Cai C, Piao J, Ning J, Huang X. Efficient two-stage designs and proper inference for animal studies. Stat Biosci 10(1):217-232, 2018. e-Pub 2018. PMID: 30294384.
161. Cai C, Ning J, Huang X. A Bayesian multi-stage cost-effectiveness design for animal studies in stroke research. Stat Methods Med Res 27(4):1219-1229, 2018. e-Pub 2018. PMID: 27405325.
162. Shen W, Ning J, Yuan Y, Lok AS, Feng Z. Model-free scoring system for risk prediction with application to hepatocellular carcinoma study. Biometrics 74(1):239-248, 2018. e-Pub 2018. PMID: 28742219.
163. Piao J, Ning J, Chambers CD, Xu R. Semiparametric Model and Inference for Spontaneous Abortion Data with a Cured Proportion and Biased Sampling. Biostatistics 19(1):54-70, 2018. e-Pub 2018. PMID: 28525542.
164. Li L, Wu CH, Ning J, Huang X, Tina Shih YC, Shen Y. Semiparametric Estimation of Longitudinal Medical Cost Trajectory. J Am Stat Assoc 113(522):582-592, 2018. e-Pub 2018. PMID: 30853736.
165. Kandl TJ, Sagiv O, Curry JL, Ning J, Ma J, Hudgens CW, Van Arnam J, Wargo JA, Esmaeli B, Tetzlaff MT. High expression of PD-1 and PD-L1 in ocular adnexal sebaceous carcinoma. Oncoimmunology 7(9):e1475874, 2018. e-Pub 2018. PMID: 30228943.
166. Xia F, Ning J, Huang X. Empirical Comparison of the Breslow Estimator and the Kalbfleisch Prentice Estimator for Survival Functions. J Biom Biostat 9(392), 2018. e-Pub 2018. PMID: 30370174.
167. Dahlstrom KR, Anderson KS, Field MS, Chowell D, Ning J, Li N, Wei Q, Li G, Sturgis EM. Diagnostic accuracy of serum antibodies to human papillomavirus type 16 early antigens in the detection of human papillomavirus-related oropharyngeal cancer. Cancer 123(24):4886-4894, 2017. e-Pub 2017. PMID: 28898394.
168. Daver N, Kantarjian H, Garcia-Manero G, Jabbour E, Borthakur G, Brandt M, Pierce S, Vaughan K, Ning J, Nogueras González GM, Patel K, Jorgensen J, Pemmaraju N, Kadia T, Konopleva M, Andreeff M, DiNardo C, Cortes J, Ward R, Craig A, Ravandi F. Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk MDS. Haematologica 102(10):1709-1717, 2017. e-Pub 2017. PMID: 28729302.
169. Showalter J, Nguyen ND, Baba S, Lee CH, Ning J, Klein K, Wahed MA, Tholpady A. Platelet Aggregometry Cannot Identify Uremic Platelet Dysfunction in Heart Failure Patients Prior to Cardiac Surgery. J Clin Lab Anal 31(5), 2017. e-Pub 2017. PMID: 27797407.
170. Thuro BA, Ning J, Peng SA, Pace ST, Dudeja G, Ozgur O, Turturro F, Samaniego F, Hagemeister FB, Fayad LE, Fowler NH, Pinnix CC, Debnam JM, Esmaeli B. Rates of Positive Findings on Positron Emission Tomography and Bone Marrow Biopsy in Patients with Ocular Adnexal Lymphoma. Ophthalmic Plast Reconstr Surg 33(5):355-360, 2017. e-Pub 2017. PMID: 27636243.
171. Ning J, Rahbar MH, Choi S, Piao J, Hong C, Del Junco DJ, Rahbar E, Fox EE, Holcomb JB, Wang MC. Estimating the Ratio of Multivariate Recurrent Event Rates with Application to a Blood Transfusion Study. Stat Methods Med Res 26(4):1969-1981, 2017. e-Pub 2017. PMID: 26160825.
172. Ning J, Chen Y, Piao J. Maximum Likelihood Estimation and EM Algorithm of Copas-Like Selection Model for Publication Bias Correction. Biostatistics 18(3):495-504, 2017. e-Pub 2017. PMID: 28334132.
173. Pfeiffer ML, Ozgur OK, Myers JN, Peng A, Ning J, Zafereo ME, Thakar S, Thuro B, Prieto VG, Ross MI, Esmaeli B. Sentinel Lymph Node Biopsy for Ocular Adnexal Melanoma. Acta Ophthalmol 95(4):e323-e328, 2017. e-Pub 2017. PMID: 27775232.
174. Ning J, Hong C, Li L, Huang X, Shen Y. Estimating treatment effects in observational studies with both prevalent and incident cohorts. Can J Stat 45(2):201-219, 2017. e-Pub 2017. PMID: 29056817.
175. Nagarajan P, Curry JL, Ning J, Piao J, Torres-Cabala CA, Aung PP, Ivan D, Ross MI, Levenback CF, Frumovitz M, Gershenwald JE, Davies MA, Malpica A, Prieto VG, Tetzlaff MT. Tumor thickness and mitotic rate robustly predict melanoma-specific survival in patients with primary vulvar melanoma: A retrospective review of 100 cases. Clin Cancer Res 23(8):2093-2104, 2017. e-Pub 2017. PMID: 27864417.
176. Chen Y, Liu Y, Ning J, Nie L, Zhu H, Chu H. A composite likelihood method for bivariate meta-analysis in diagnostic systematic reviews. Stat Methods Med Res 26(2):914-930, 2017. e-Pub 2017. PMID: 25512146.
177. Choi S, Huang X, Ju H, Ning J. Semiparametric accelerated intensity models for correlated recurrent and terminal events. Stat Sin 27(2):625-643, 2017. e-Pub 2017.
178. Arora K, Kelley J, Sui D, Ning J, Martinez F, Lichtiger B, Tholpady A. Cancer Type Predicts Alloimmunization Following RhD Incompatible RBC Transfusions. Transfusion 57(4):952-958, 2017. e-Pub 2017. PMID: 28191636.
179. Chen Y, Ning J, Ning Y, Liang KY, Bandeen-Roche K. On pseudolikelihood inference for semiparametric models with boundary problems. Biometrika 104(1):165-179, 2017. e-Pub 2017. PMID: 29430029.
180. Liu H, Shen Y, Ning J, Qin J. Sample Size Calculations for Prevalent Cohort Designs. Stat Methods Med Res 26(1):280-291, 2017. e-Pub 2017. PMID: 25091809.
181. Shen Y, Ning J, Qin J. Nonparametric and Semiparametric Regression Estimation for Length-biased Survival Data. Lifetime Data Anal 23(1):3-24, 2017. e-Pub 2017. PMID: 27086362.
182. Zhu H, Ning J, Shen Y, Qin J. Semiparametric density ratio modeling of survival data from a prevalent cohort. Biostatistics 18(1):62-75, 2017. e-Pub 2017. PMID: 27354710.
183. Wen S, Ning J, Collins S, Berry D. A Response-Adaptive Design of Initial Therapy for Emergency Department Patients with Heart Failure. Contemp Clin Trials 52:46-53, 2017. e-Pub 2017. PMID: 27838474.
184. Fournier K, Rafeeq S, Taggart M, Kanaby P, Ning J, Chen HC, Overman M, Raghav K, Eng C, Mansfield P, Royal R. Low-grade Appendiceal Mucinous Neoplasm of Uncertain Malignant Potential (LAMN-UMP): Prognostic Factors and Implications for Treatment and Follow-up. Ann Surg Oncol 24(1):187-193, 2017. e-Pub 2017. PMID: 27660258.
185. Zhou R, Zhu H, Bondy M, Ning J. Analyzing semi-competing risks data with missing cause of informative terminal event. Stat Med 36(5):738-753, 2017. e-Pub 2017. PMID: 27813148.
186. Shen W, Ning J, Yuan Y. Rate-adaptive Bayesian independent component analysis. Electronic Journal of Statistics 10(2):3247-3264, 2016. e-Pub 2016.
187. Liang L, Jiang Y, Chen JS, Niu N, Piao J, Ning J, Zu Y, Zhang J, Liu J. B7-H4 Expression in Ovarian Serous Carcinoma: A Study of 306 Cases. Hum Pathol 57:1-6, 2016. e-Pub 2016. PMID: 27349304.
188. Alatrash G, Thall PF, Valdez BC, Fox PS, Ning J, Garber HR, Janbey S, Worth LL, Popat U, Hosing C, Alousi AM, Kebriaei P, Shpall EJ, Jones RB, de Lima M, Rondon G, Chen J, Champlin RE, Andersson BS. Long-term Outcomes After Treatment with Clofarabine ± Fludarabine with Once Daily IV Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and MDS. Biol Blood Marrow Transplant 22(10):1792-800, 2016. e-Pub 2016. PMID: 27377901.
189. Tamamyan GN, Kantarjian HM, Ning J, Jain P, Sasaki K, McClain KL, Allen CE, Pierce SA, Cortes JE, Ravandi F, Konopleva MY, Garcia-Manero G, Benton CB, Chihara D, Rytting ME, Wang S, Abdelall W, Konoplev SN, Daver NG. Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes. Cancer 122(18):2857-66, 2016. e-Pub 2016. PMID: 27244347.
190. Tetzlaff MT, Singh RR, Seviour EG, Curry JL, Hudgens CW, Bell D, Wimmer DA, Ning J, Czerniak BA, Zhang L, Davies MA, Prieto VG, Broaddus RR, Ram P, Luthra R, Esmaeli B. Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma. J Pathol 240(1):84-95, 2016. e-Pub 2016. PMID: 27287813.
191. Choi S, Rahbar MH, Ning J, Del Junco DJ, Rahbar E, Hong C, Piao J, Fox EE, Holcomb JB. Recurrent event frailty models reduced time-varying and other biases in evaluating transfusion protocols for traumatic hemorrhage. J Clin Epidemiol 77:52-59.e1, 2016. e-Pub 2016. PMID: 27134138.
192. Zhou R, Zhu H, Bondy M, Ning J. Semiparametric Model for Semi-competing Risks Data with Application to Breast Cancer Study. Lifetime Data Anal 22(3):456-71, 2016. e-Pub 2016. PMID: 26340889.
193. Liu H, Ning J, Qin J, Shen Y. Semiparametric maximum likelihood inference for truncated or biased-sampling data. Stat Sin 26(3):1087-1115, 2016. e-Pub 2016.
194. Ning J, Rahbar MH, Choi S, Hong C, Piao J, del Junco DJ, Fox EE, Rahbar E, Holcomb JB. A joint latent class analysis for adjusting survival bias with application to a trauma transfusion study. Stat Med 35(1):65-77, 2016. e-Pub 2016. PMID: 26256455.
195. Clemens MW, Medeiros LJ, Butler CE, Hunt KK, Fanale MA, Horwitz S, Weisenburger DD, Liu J, Morgan EA, Kanagal-Shamanna R, Parkash V, Ning J, Sohani AR, Ferry JA, Mehta-Shah N, Dogan A, Liu H, Thormann N, Di Napoli A, DiNapoli A, Lade S, Piccolini J, Reyes R, Williams T, McCarthy CM, Hanson SE, Nastoupil LJ, Gaur R, Oki Y, Young KH, Miranda RN. Complete Surgical Excision is Essential for the Management of Patients with Breast Implant-Associated Anaplastic Large Cell Lymphoma. J Clin Oncol 34(2):160-8, 2016. e-Pub 2016. PMID: 26628470.
196. Huang X, Yan F, Ning J, Feng Z, Choi S, Cortes J. A two-stage approach for dynamic prediction of time-to-event distributions. Stat Med 35(13):2167-82, 2016. e-Pub 2016. PMID: 26748812.
197. Ning J, Peng S, Ueno N, Xu Y, Shih Y, Karuturi M, Giordano S, Shen Y. Has Racial Difference in Cause-Specific Death Improved in Older Patients with Late-Stage Breast Cancer?. Ann Oncol 26(10):2161-8, 2015. e-Pub 2015. PMID: 26223248.
198. Huang CY, Ning J, Qin J. Semiparametric likelihood inference for left-truncated and right censored data. Biostatistics 16(4):785-98, 2015. e-Pub 2015. PMID: 25796430.
199. Chen Y, Ning J, Cai C. Regression analysis of longitudinal data with irregular and informative observation times. Biostatistics 16(4):727-39, 2015. e-Pub 2015. PMID: 25813646.
200. Shen W, Ning J, Yuan Y. Bayesian sequential monitoring design for two-arm randomized clinical trials with noncompliance. Stat Med 34(13):2104-15, 2015. e-Pub 2015. PMID: 25756852.
201. Ning J, Chen Y, Cai C, Huang X, Wang MC. On the Dependence Structure of Bivariate Recurrent Event Processes: Inference and Estimation. Biometrika 102(2):345-358, 2015. e-Pub 2015.
202. Chen Y, Liu Y, Ning J, Cormier J, Chu H. A hybrid model for combining case-control and cohort studies in systematic reviews of diagnostic tests. J R Stat Soc Ser C Appl Stat 64(3):469-489, 2015. e-Pub 2015. PMID: 25897179.
203. Shen W, Ning J, Yuan Y. A direct method to evaluate the time-dependent predictive accuracy for biomarkers. Biometrics 71(2):439-49, 2015. e-Pub 2015. PMID: 25758584.
204. Rahbar MH, Ning J, Choi S, Piao J, Hong C, Huang H, Del Junco DJ, Fox EE, Rahbar E, Holcomb JB. A joint latent class model for classifying severely hemorrhaging trauma patients. BMC Res Notes 8:602, 2015. e-Pub 2015. PMID: 26498438.
205. Tang X, Alatrash G, Ning J, Jakher H, Stafford P, Zope M, Shpall EJ, Jones RB, Champlin RE, Thall PF, Andersson BS. Increasing Chimerism Following Allogeneic Stem Cell Transplantation is Associated with Longer Survival Time. Biol Blood Marrow Transplant 20(8):1139-44, 2014. e-Pub 2014. PMID: 24727332.
206. Huang X, Ning J, Wahed AS. Optimization of individualized dynamic treatment regimes for recurrent diseases. Stat Med 33(14):2363-78, 2014. e-Pub 2014. PMID: 24510534.
207. Ning J, Bandeen-Roche K. Estimation of time-dependent association for bivariate failure times in the presence of a competing risk. Biometrics 70(1):10-20, 2014. e-Pub 2014. PMID: 24350628.
208. Zhou JH, Kim KB, Myers JN, Fox PS, Ning J, Bassett RL, Hasanein H, Prieto VG. Immunohistochemical expression of hormone receptors in melanoma of pregnant women, non-pregnant women and men. Am J Dermatopathol 36(1):74-9, 2014. e-Pub 2014. PMID: 23812018.
209. Ning J, Qin J, Shen Y. Semiparametric accelerated failure time model for length-biased data with application to dementia study. Stat Sin 24(1):313-333, 2014. e-Pub 2014. PMID: 24478570.
210. Ning J, Qin J, Shen Y. Score Estimating Equations from Embedded Likelihood Functions under Accelerated Failure Time Model. J Am Stat Assoc 109(508):1625-1635, 2014. e-Pub 2014. PMID: 25663727.
211. Takahashi K, Pemmaraju N, Strati P, Nogueras-Gonzalez G, Ning J, Bueso-Ramos C, Luthra R, Pierce S, Cortes J, Kantarjian H, Garcia-Manero G. Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia. Blood 122(16):2807-11, 2013. e-Pub 2013. PMID: 23896412.
212. Badgwell B, Stanley J, Chang GJ, Katz MH, Lin HY, Ning J, Klimberg SV, Cormier JN. Comprehensive geriatric assessment of risk factors associated with adverse outcomes and resource utilization in cancer patients undergoing abdominal surgery. J Surg Oncol 108(3):182-6, 2013. e-Pub 2013. PMID: 23804149.
213. Liu S, Cai C, Ning J. Up-and-down designs for phase I clinical trials. Contemp Clin Trials 36(1):218-227, 2013. e-Pub 2013. PMID: 23856381.
214. Liu S, Ning J. A bayesian dose-finding design for drug combination trials with delayed toxicities. Bayesian Anal 8(3):703-722, 2013. e-Pub 2013. PMID: 27924182.
215. Trickey AW, Fox EE, Del Junco DJ, Ning J, Holcomb JB, Brasel KJ, Cohen MJ, Schreiber MA, Bulger EM, Phelan HA, Alarcon LH, Myers JG, Muskat P, Cotton BA, Wade CE, Rahbar MH. The impact of missing trauma data on predicting massive transfusion. J Trauma Acute Care Surg 75:S68-S74, 2013. e-Pub 2013. PMID: 23936751.
216. Rahbar MH, del Junco DJ, Huang H, Ning J, Fox EE, Zhang X, Schreiber MA, Brasel KJ, Bulger EM, Wade CE, Cotton BA, Phelan HA, Cohen MJ, Myers JG, Alarcon LH, Muskat P, Holcomb JB, Group PS. A latent class model for defining severe hemorrhage: experience from the PROMMTT study. J Trauma Acute Care Surg 75(1 Suppl 1):S82-8, 2013. e-Pub 2013. PMID: 23778516.
217. Ning J, Qin J, Asgharian M, Shen Y. Empirical likelihood-based confidence intervals for length-biased data. Stat Med 32(13):2278-91, 2013. e-Pub 2013. PMID: 23027662.
218. Hwang KO, Ning J, Trickey AW, Sciamanna CN. Website usage and weight loss in a free commercial online weight loss program: retrospective cohort study. J Med Internet Res 15(1):e11, 2013. e-Pub 2013. PMID: 23322819.
219. Huang X, Ning J. Analysis of multi-stage treatments for recurrent diseases. Stat Med 31(24):2805-21, 2012. e-Pub 2012. PMID: 22826139.
220. Shen Y, Ning J, Qin J. Likelihood approaches for the invariant density ratio model with biased-sampling data. Biometrika 99(2):363-378, 2012. e-Pub 2012. PMID: 23843663.
221. Rahbar MH, Chen Z, Jeon S, Gardiner JC, Ning J. A nonparametric test for equality of survival medians. Stat Med 31(9):844-54, 2012. e-Pub 2012. PMID: 22302559.
222. Diao G, Ning J, Qin J. Maximum likelihood estimation for semiparametric density ratio model. Int J Biostat 8(1), 2012. e-Pub 2012. PMID: 22745024.
223. Ning J, Qin J, Shen Y. Buckley-James-type estimator with right-censored and length-biased data. Biometrics 67(4):1369-1378, 2011. e-Pub 2011. PMID: 21385160.
224. Qin J, Ning J, Liu H, Shen Y. Maximum likelihood estimations and EM algorithms with length-biased data. J Am Stat Assoc 106(496):1434-1449, 2011. e-Pub 2011. PMID: 22323840.
225. Ning J, Qin J, Shen Y. Nonparametric tests for right-censored data with biased sampling. J R Stat Soc Series B Stat Methodol 72(5):609-630, 2010. e-Pub 2010. PMID: 21031144.
226. Ning J, Huang X. Response-adaptive randomization for clinical trials with adjustment for covariate imbalance. Stat Med 29(17):1761-8, 2010. e-Pub 2010. PMID: 20658546.
227. Shen Y, Ning J, Qin J. Analyzing length-biased data with semiparametric transformation and accelerated failure time models. J Am Stat Assoc 104(487):1192-1202, 2009. e-Pub 2009. PMID: 21057599.
228. Huang X, Ning J, Li Y, Estey E, Issa JP, Berry DA. Using short-term response information to facilitate adaptive randomization for survival clinical trials. Stat Med 28(12):1680-9, 2009. e-Pub 2009. PMID: 19326367.
229. Bandeen-Roche K, Ning J. Non-parametric estimation of bivariate failure time associations in the presence of a competing risk. Biometrika 95(1):221-232, 2008. e-Pub 2008. PMID: 20305739.
230. Hui J, Miao B, Ning J, Peng H. Nonparametric estimation for contamination distribution. Applied Mathematics 23(2):175-182, 2008. e-Pub 2008.
231. Lei M, Miao B, Ning J. Study of Shanghai stock index and the policy effect with survival analysis. Application of Statistics and Management 22(6):46-50, 2003. e-Pub 2003.
232. Miao B, Ning, J, Xiao J, Dai X. Statistical Analysis and amendment of evaluation data. Journal of University of Science and Technology of China 32(1):56-61, 2002. e-Pub 2002.
233. Li H, Ning J, Fang Z. Logistic model for the questionnaire about environment protecting consciousness. Application of Statistics and Management 21(3):6-10, 2002. e-Pub 2002.
234. Miao B, Xiao J, Ning J, Zhang W. Statistics Analysis and prediction on the market of cement industry. Operations Research and Management Science 10(4):120-125, 2001. e-Pub 2001.
235. Ning J, Xiao J, Miao B. Analysis of fatty liver and its influencing factors. Application of Statistics and Management 12(3):9-12, 2001. e-Pub 2001.
236. Miao B, Ning J, Xiao J. The application of principal component and factor analysis in analyzing physical examination data. Application of Statistics and Management 19(6):16-19, 2000. e-Pub 2000.

Invited Articles

1. Ning J. Discussion of ‘A selective review of statistical methods using calibration information from similar studies’. Statistical Theory and Related Fields 6:199-200, 2022. e-Pub 2022.
2. Ning J. Book review of Biased Sampling, Over-identified Parameter Problems and Beyond. Journal of the American Statistical Association 113(522):948-953, 2018. e-Pub 2018.

Other Articles

1. Nagarajan P, Piao J, Ning J, Noordenbos LE, Curry JL, Torres-Cabala CA, Diwan AH, Ivan D, Aung PP, Ross MI, Royal RE, Wargo JA, Wang WL, Samdani R, Lazar AJ, Rashid A, Davies MA, Prieto VG, Gershenwald JE, Tetzlaff MT Corrigendum to "Prognostic Model for Patient Survival in Primary Anorectal Mucosal Melanoma: Stage at Presentation Determines Relevance of Histopathologic Features" [Modern Pathology 33 (2020) 496-513]. Mod Pathol 38(8):100819, 2025. PMID: 40541156.

Book Chapters

1. Huang X, Qiao W, Ning J. Innovative Clinical Trial Designs for Precision Medicine. In: the fifth editions of The MD Anderson Manual of Medical Oncology, 2025.
2. Huang X, Qiao W, Xia F, Lin E, Zhu L, Ning J. Statistical Designs for Oncology Clinical Trials. In: The MD Anderson Manual of Medical Oncology,Fourth Edition, 2022.
3. Yuan Y, Ning J. Covariate-balanced Bayesian adaptive randomization: achieving tradeo between inferential and ethical goals in small and moderate size trials. In: Modern Adaptive Randomized Clinical Trials: Statistical, Operational, and Regulatory Aspects. CRC Press, 2015.

Letters to the Editor

1. Swaminathan, M, DiNardo, C, Maiti, A, Pemmaraju, N, Ohanian, M, Daver, NG, Garcia-Manero, G, Issa, GC, Borthakur, G, Ravandi-Kashani, F, Montalban Bravo, G, Kadia, TM, Alvarado, Y, Jabbour, EJ, Short, NJ, Wierda, WG, Jain, N, Kornblau, SM, Masarova, L, Pierce, S, Qiao, W, Ning, J, Kantarjian, HM, Konopleva, M. VEN in combination with 10-day DEC in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome. Blood cancer journal 15, 2025.